Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?

被引：67

作者：

Livermore, DM ^{[1
]}

机构：

[1] Cent Publ Hlth Lab, Antibiot Resistance Monitoring & Reference Lab, London NW9 5HT, England

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2000年 / 46卷 / 03期

关键词：

D O I：

10.1093/jac/46.3.347

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

[No abstract available]

引用

页码：347 / 350

页数：4

共 26 条

[1]

BAGER F, 1999, DANMAP 98 CONSUMPTIO

[2]

BIRMINGHAM MC, 1999, 37 ANN M INF DIS SOC, P62

[3]

BIRMINGHAM MC, 1999, 39 INT C ANT AG CHEM, P724

[4] A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones' [J].

Blondeau, JM .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 :1-11

[5] Time-kill kinetics of quinupristin/dalfopristin on Staphylococcus aureus with and without a raised MBC evaluated by two methods [J].

Boswell, FJ ;

Sunderland, J ;

Andrews, JM ;

Wise, R .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 :29-32

[6]

BUCHANAN L, 1999, 37 ANN M INF DIS SOC, P52

[7] Inhibition of protein synthesis by streptogramins and related antibiotics [J].

Cocito, C ;

DiGiambattista, M ;

Nyssen, E ;

Vannuffel, P .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 :7-13

[8]

*CUB PHARM INC, 1999, DAPT BACKGR

[9]

Dresser LD, 1998, PHARMACOTHERAPY, V18, P456

[10]

FAGON JY, 1997, 20 INT C CHEM ICC SY, P44

← 1 2 3 →